PLBIO(000403)2024-10-09 10:44Financial Performance - The net profit attributable to shareholders for the first three quarters of 2024 is expected to be between 521.91 million and 554.53 million CNY, representing a year-on-year growth of 60% to 70%[6]. - The net profit after deducting non-recurring gains and losses is projected to be between 485.53 million and 512.51 million CNY, indicating a year-on-year increase of 80% to 90%[6]. - Basic earnings per share are estimated to be between 0.7140 CNY and 0.7587 CNY, compared to 0.4460 CNY in the same period last year[4]. - For the third quarter of 2024, the net profit attributable to shareholders is expected to be between 201.36 million and 228.82 million CNY, reflecting a year-on-year growth of 10% to 25%[5]. - The net profit after deducting non-recurring gains and losses for Q3 2024 is projected to be between 190.35 million and 215.17 million CNY, with a year-on-year increase of 15% to 30%[5]. Growth Drivers - The growth in net profit is primarily driven by an increase in raw plasma collection and a favorable market demand for blood products[6]. - The company anticipates an increase in the number and sales volume of its available products for the first three quarters of 2024[6]. Financial Reporting and Risks - The financial data provided is preliminary and has not been audited by an accounting firm, with detailed financial results to be disclosed in the Q3 2024 report[7]. - The company emphasizes the importance of investors being aware of investment risks related to the preliminary financial forecasts[7]. - The designated information disclosure media for the company is the Securities Times and the CNINFO website[7].